Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Additional Reading from MarketBeat The 3 Penny Stocks You Swore You'd Never Buy (But You'll Check Anyway)Written by Chris Markoch. Date Posted: 1/18/2026. 
At a Glance - Vaxart is a clinical-stage biotech developing oral vaccines that could transform global immunization if its platform proves effective.
- Microvision develops cost-effective lidar technology for autonomous vehicles, with upside tied to industry adoption and potential partnerships.
- Datavault AI focuses on monetizing digital data through AI and blockchain tools, offering speculative exposure to the emerging data-as-an-asset theme.
Penny stocks attract speculative investors seeking high-risk, high-reward opportunities. Investors often look for companies with disruptive technologies, exposure to emerging trends, or compelling turnaround stories. Many of these businesses will never scale or survive, but if just one succeeds, it can deliver outsized returns. For investors who believe strength lies in numbers, MarketBeat offers a tool that lists the 100 Most Popular Penny Stocks. That ranking is based on the number of MarketBeat subscribers following each company. While popularity is no guarantee of success, it can provide additional conviction for some investors. There are five truths reshaping America's financial future — and ignoring them could be costly. From an overextended government and vanishing savings to AI-driven job displacement and a widening wealth divide, the warning signs are clear. But according to Porter Stansberry, these same forces are also driving one of the largest wealth transfers in history. His new exposé, The Final Displacement, reveals the economic blueprint behind these shifts — and the final step he believes every American must take to protect and grow their wealth before it's too late. Click here to watch The Final Displacement for free Some investors define a penny stock as any stock trading for $5 or less. The stocks in this screener, however, follow the traditional definition—shares priced below $1. These names are highly volatile. Do your own research and confirm your risk tolerance before initiating a position. Vaxart: A Potential Game-Changer for Global Immunization Efforts Vaxart Inc. (NASDAQ: VXRT) is a clinical-stage biotechnology company developing oral vaccines for infectious diseases such as influenza, norovirus, and COVID-19. Unlike traditional injectable vaccines, Vaxart's tablet-based platform aims to simplify distribution and improve global accessibility. The bull case for Vaxart centers on its innovative delivery approach. If the company secures FDA approval and successfully scales manufacturing and distribution, its oral vaccines could lower logistical barriers to mass immunization and create opportunities for licensing partnerships. Positive trial results or a commercial collaboration could meaningfully shift sentiment and valuation given the stock's current low base. Clinical risk is the primary challenge. Vaxart has not yet commercialized a product, and vaccine development is costly and unpredictable. Competition from established players with larger R&D budgets also constrains visibility. For now, Vaxart is a long-term speculative bet on platform validation rather than near-term profitability. The MarketBeat analyst ratings show only one analyst covering VXRT, which should give prospective investors pause. The stock has roughly 18% institutional ownership, while short interest is about 2%, a figure that may help limit some volatility. Microvision: Developing Cost-Effective LiDAR Units for Autonomous Driving Microvision Inc. (NASDAQ: MVIS) develops LiDAR (light detection and ranging) sensors used in autonomous vehicles, smart infrastructure, and industrial sensing. The company's hardware and software enable precise 3D mapping required for self-driving and advanced driver-assistance systems (ADAS). Microvision focuses on compact, cost-effective LiDAR units that could appeal to automakers seeking scalable sensor solutions. The bull case for Microvision rests on two factors: the ongoing push toward vehicle automation and potential partnerships with major automotive manufacturers. If the company can demonstrate performance or cost advantages, it could secure supply agreements or licensing deals that improve revenue visibility. Microvision's technology may also find uses beyond vehicles—such as robotics and smart cities—adding optionality to its growth story. Despite the potential, Microvision faces stiff competition from LiDAR specialists like Luminar (NASDAQ: LAZR), Innoviz (NASDAQ: INVZ), and Ouster (NYSE: OUST). The timeline to widespread commercial adoption has been slower than many hoped, and the path to profitability remains uncertain. MVIS is covered by three analysts and has a consensus price target of $2.50, implying a potential 169% gain from its Jan. 15 closing price. Like many speculative names, Microvision has modest institutional ownership (around 30%) and elevated short interest (around 21%), so investors should expect high volatility. Datavault AI: Trying to Democratize Data Ownership Datavault AI Inc. (NASDAQ: DVLT) operates at the intersection of artificial intelligence, data monetization, and digital asset management. The company helps organizations convert raw data into tradable, revenue-generating assets through its patented Datavault platform. By combining AI, blockchain, and analytics, Datavault AI aims to democratize data ownership and unlock monetization opportunities that traditional systems may miss. The bullish case for Datavault AI rests on its niche focus and potential scalability. As data becomes increasingly valuable, businesses—and individuals—are seeking secure ways to monetize digital information. Datavault's technology could benefit from broader AI adoption and growing interest in data sovereignty. Early traction or strategic partnerships might boost investor confidence. That said, Datavault AI operates in a highly experimental space. Its business model is still evolving, and the path to meaningful revenue growth is unproven. Institutions own less than 1% of the stock, and short interest exceeds 16% as of this writing. Investors should view DVLT as a long-term, speculative position based on belief in data-as-an-asset innovation rather than near-term earnings potential.
| 
